A Study of AZD0486 Monotherapy or in Combination with Other Anti-Cancer Agents for Mature B-Cell Malignancies

Trial Identifier: D7407C00001
Sponsor: AstraZeneca
Start Date: January 2025
Primary Completion Date: April 2031
Study Completion Date: April 2031

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Heidelberg, AU, 3084
AU Melbourne, AU, 3004
AU Nedlands, AU, 6009
CN Beijing, CN, 100044
CN Guangzhou, CN, 510060
CN Jinan, CN, 250013
CN Tianjin, CN, 300060
CN Zhengzhou, CN, 450008
CZ Ostrava - Poruba, CZ, 708 52
CZ Praha 2, CZ, 12808
CZ Praha 2 - Nové Město, CZ, 12820
DE Kiel, DE, 24105
DE München, DE, 81377
DE Wuerzburg, DE, 97080
DK Aalborg, DK, 9000
DK Aarhus N, DK, 8200
DK Copenhagen, DK, 2100
ES Barcelona, ES, 8036
ES Madrid, ES, 28040
ES Madrid, ES, 28034
ES Palma de Mallorca, ES, 7120
ES Santiago de Compostela, ES, 15706
ES Valencia, ES, 46026
FR Montpellier, FR, 34295
FR Paris, FR, 75010
FR Saint Cloud, FR, 92210
FR Villejuif Cedex, FR, 94805
GB Derriford, GB, PL6 5FP
GB London, GB, SE5 9RS
GB Oxford, GB, 0X3 7LJ
JP Koto-ku, JP, 135-8550
JP Matsuyama-shi, JP, 791-0280
JP Nagoya-shi, JP, 464-8681
KR Busan, KR, 48108
KR Seoul, KR, 05505
KR Seoul, KR, 03080
KR Seoul, KR, 06591
KR Seoul, KR, 06351
KR Seoul, KR, 02841
TW Changhua, TW, 500
TW Kaohsiung City, TW, 83301
TW Tainan, TW, 710
TW Taipei, TW, 100
US, MA Boston, MA, US, 02215
US, NC Charlotte, NC, US, 28204
US, NJ New Brunswick, NJ, US, 08901
US, NY New York, NY, US, 10029
US, OR Portland, OR, US, 97239
US, PA Philadelphia, PA, US, 19104
US, RI Providence, RI, US, 02903